5Y leads $74m round for China AI drug developer
Beijing-based HeliXon, an artificial intelligence-enabled developer of protein-based drugs, has raised CNY 500m (USD 75m) in Series A funding led by 5Y Capital. Other investors include Gaorong Capital and Neumann Capital.
Three existing backers - Xiang He Capital, GL Ventures, and Qingzhi Capital - re-upped in the Series A. They provided an angel round last year. HeliXon was founded in June 2021 by Jian Peng, formerly...
More on Greater China
Latest News
Singapore-based Timothy Zee leaves PAG
Timothy Zee, a Singapore-based managing director with PAG whose primary responsibilities included deal sourcing and business development, has left the firm after 10 years.
Bertelsmann to invest $500m in India
Bertelsmann India Investments has earmarked USD 500m, provided by its eponymous German parent, for investment in local start-ups. The VC unit’s total deployment since its launch in 2013 is USD 285m.
Entrepreneur First raises $158m, targets SE Asia
UK-headquartered incubator Entrepreneur First (EF) has raised USD 158m, targeted in part at investment in Southeast Asian start-ups and expanding its reach in the region.
CDH exits New Zealand supplements brand to Nestle
CDH Investments has agreed to sell New Zealand-based supplements manufacturer The Better Health Company (TBHC) to Nestlé Health Science for an undisclosed sum.